How Ivermectin Fights Cancer Cells: 5 Mechanisms Explained

How Ivermectin Fights Cancer Cells: 5 Mechanisms Explained

Ivermectin has been used safely in hundreds of millions of people for decades as an antiparasitic treatment. But a quieter story has been unfolding in oncology research labs since the 1990s — one that reveals ivermectin as a surprisingly versatile anti-cancer compound. This is not a story of a single trick. Ivermectin appears to interfere with cancer cell biology through multiple distinct biological pathways, each attacking a different vulnerability that cancer cells rely on to grow, survive, resist treatment, and evade the immune system.

This article takes a deep look at five specific molecular mechanisms by which ivermectin has been shown, in preclinical laboratory and animal research, to act against cancer cells — plus a sixth bonus mechanism involving the immune system. Each section explains the science in plain terms and cites the peer-reviewed studies behind the findings. For readers already familiar with ivermectin's broader research landscape, you may also want to read our companion article: Ivermectin and Cancer: What Does the Research Say?

A Multi-Targeted Compound: Why Five Mechanisms Matter

Most cancer drugs work by targeting one specific molecule or pathway. This focused approach has produced genuine breakthroughs, but it also has a well-documented weakness: cancer cells are genetically unstable and evolve rapidly. When a drug hits a single target, cancer cells can often mutate around it, developing resistance within months or years. This is one reason why combination therapies — drugs that attack cancer from multiple angles simultaneously — have become standard of care for many cancers.

Ivermectin is unusual because it appears to engage cancer biology at multiple independent points simultaneously. It is not targeting one protein in one pathway. The research shows interference with signaling kinases, ion channels, mitochondrial metabolism, transcription factor networks, drug efflux pumps, and the tumor microenvironment. For a compound that was originally developed to paralyze parasitic worms, this breadth of anti-cancer activity has been a significant scientific surprise — and the subject of growing interest in oncology drug repositioning research.

Understanding each mechanism individually provides a clearer picture of why ivermectin shows activity across such a wide range of cancer types in laboratory research, including breast, colon, lung, ovarian, glioblastoma, leukemia, and melanoma.

Mechanism 1: PAK1 Degradation and Autophagy Induction

Understanding PAK1: A Master Growth Regulator

PAK1, or p21-activated kinase 1, is a protein kinase — essentially a molecular switch — that regulates cell growth, survival, and division. In many types of cancer, PAK1 is overexpressed or hyperactivated, making it a useful target for anti-cancer therapy. PAK1 exerts much of its pro-cancer effect by activating a downstream signaling chain: PAK1 activates Akt, which activates mTOR (mechanistic target of rapamycin). The Akt/mTOR pathway is one of the most important growth-promoting pathways in the human body. When it is constitutively "on" inside cancer cells, it drives uncontrolled proliferation and suppresses a natural clean-up process called autophagy.

Autophagy is literally translated from Greek as "self-eating." It is a cellular recycling system in which cells break down damaged or unnecessary components. In modest amounts, autophagy helps cells survive stress. But when autophagy is pushed to excess, it becomes a form of programmed cell death — the cell essentially consumes itself beyond the point of recovery. This form of cell death is called cytostatic autophagy, and it is distinct from the more commonly discussed apoptosis (programmed cell death via a different pathway).

How Ivermectin Targets PAK1

A landmark 2016 study published in Cancer Research by Dou and colleagues (PMC5173258) identified the precise molecular mechanism by which ivermectin attacks breast cancer cells. The researchers found that ivermectin promotes the ubiquitination of PAK1 — essentially flagging the protein for disposal by attaching ubiquitin molecules to it. The proteasome, the cell's protein-degradation machinery, then recognizes the ubiquitin tag and degrades PAK1. The proof was clear: when the researchers added a proteasome inhibitor called MG132, it blocked ivermectin's ability to reduce PAK1 levels, confirming that degradation was happening via the ubiquitin-proteasome pathway.

The consequence of PAK1 loss is a cascade of downstream effects. Without PAK1, the phosphorylation (activation) of Akt is reduced. Without active Akt, the mTOR pathway is suppressed. When mTOR is inactive, autophagy is no longer held in check. The result: an uncontrolled surge in autophagic activity inside the cancer cell — an internal demolition that does not stop in time, ultimately leading to cell death.

The study demonstrated this in breast cancer cell lines (MCF-7 and MDA-MB-231) and validated it in mouse xenograft models. When PAK1 was artificially knocked down using siRNA (genetic silencing), the anti-cancer effect of ivermectin was diminished — confirming that PAK1 is a primary mediator of this mechanism, not a side effect.

A comprehensive 2021 review by Tang and colleagues (PMC7505114) in Pharmacological Research synthesized the broader picture across cancer types. The PAK1/autophagy mechanism has been confirmed in multiple cancer models including breast cancer, ovarian cancer, glioma, nasopharyngeal carcinoma, and melanoma. In glioma cells (U251, C6), ivermectin inhibited proliferation specifically via the Akt/mTOR pathway. In melanoma cells (SK-MEL-28), the autophagy induction involved an additional pathway: ivermectin activates ROS-TFE3-dependent autophagy by dephosphorylating TFE3 at Ser321, allowing this autophagy master regulator to migrate into the nucleus and ramp up autophagic gene expression.

Markers of Autophagy Induction

Laboratory studies have documented increases in the canonical autophagy markers following ivermectin treatment: LC3-II (a marker of autophagosome formation), Beclin1, and Atg5 are all elevated. The number of autophagosomes — the membrane-bound vesicles that engulf cellular components for degradation — increases significantly. When researchers block autophagy using inhibitors like chloroquine or wortmannin, or use siRNA to silence Beclin1 or Atg5, ivermectin's anti-tumor effects are substantially reduced. This confirms that autophagy induction is not an incidental effect — it is central to the mechanism of cell death.

Mechanism 2: Chloride Ion Disruption and Mitochondrial Damage

Ivermectin as an Ionophore: A Cellular Disruptor

Ivermectin's original antiparasitic mechanism involves forcing open chloride ion channels in nematode nerve cells, causing uncontrolled chloride influx and paralysis. In mammalian cells, which lack the nematode-specific glutamate-gated chloride channels, ivermectin acts instead as an ionophore — a molecule that facilitates ion transport across cell membranes via different channels and receptors. This ionophore activity turns out to be critically relevant to cancer biology.

Cancer cells are fundamentally different from normal cells in their reliance on chloride homeostasis. Research has established that malignant cells upregulate chloride channels, making them more dependent on precise chloride balance for regulation of cell volume, intracellular pH, and calcium signaling. This dependence becomes a vulnerability: when ivermectin triggers abnormal chloride influx into cancer cells, it disrupts a finely calibrated system that normal cells can compensate for — but cancer cells often cannot.

The 2010 Discovery: Chloride-Dependent Cancer Cell Death

The foundational study on ivermectin's chloride ion mechanism was published in Blood in 2010 by researchers at the Ontario Cancer Institute (Sharmeen et al., PMID 20644115). The team screened a library of FDA-approved compounds to identify those with anti-leukemia activity and identified ivermectin as a standout candidate. The key findings were:

• Ivermectin induced cell death at low micromolar concentrations (IC50 of approximately 5 µM) in acute myeloid leukemia (AML) cell lines including HL60, KG1a, and OCI-AML2, as well as in primary patient samples.
• Normal hematopoietic cells were significantly less sensitive — ivermectin did not induce apoptosis in them at concentrations up to 20 µM — suggesting a therapeutic window.
• Ivermectin increased intracellular chloride ion concentrations and caused plasma membrane hyperpolarization.
• Ivermectin significantly increased reactive oxygen species (ROS) generation, which was functionally essential for cell death — blocking ROS rescued cells from ivermectin-induced death.
• Ivermectin showed synergistic anti-leukemia activity when combined with cytarabine and daunorubicin, both of which also induce ROS.
• In three independent mouse xenograft models of leukemia, ivermectin delayed tumor growth at pharmacologically achievable concentrations without observable toxicity.

Mitochondrial Complex I Inhibition and ATP Depletion

A 2015 study by Draganov and colleagues (PMC4639773), published in Scientific Reports, explored the purinergic signaling and mitochondrial dimensions of ivermectin's activity in triple-negative breast cancer (TNBC) cells. The study confirmed that chloride influx from ivermectin treatment triggers rapid plasma membrane hyperpolarization and initiates a downstream cascade involving mitochondrial dysfunction.

Critically, the research detailed how ivermectin inhibits mitochondrial complex I — the first protein complex in the electron transport chain, which is responsible for initiating the cascade of reactions that produces ATP (adenosine triphosphate), the cell's primary energy currency. The consequences of complex I inhibition are far-reaching:

• Reduced ATP production: Cancer cells, with their hyperactive metabolism and rapid growth demands, are acutely sensitive to energy depletion. Normal cells can often compensate; rapidly dividing cancer cells frequently cannot.
• Mitochondrial membrane potential collapse: Studies in glioblastoma cells showed that ivermectin decreases both the mitochondrial membrane potential and the electrochemical proton gradient — the driving force for ATP synthesis.
• Mitochondrial superoxide generation: The dysfunctional electron transport chain leaks electrons onto molecular oxygen, generating superoxide — a highly reactive oxygen species — which causes oxidative damage to cellular components including DNA, lipids, and proteins.
• Akt/mTOR pathway suppression: In glioblastoma cell lines (U87, T98G), ivermectin was shown to decrease the phosphorylation of Akt at Ser473, mTOR at Ser2481, and the ribosomal S6 protein — confirming that the mitochondrial effect converges on the same growth-suppressing pathway as the PAK1 mechanism.

The mechanistic link between chloride disruption and mitochondrial damage was validated using genetic and pharmacological tools: cells rendered deficient in mitochondrial respiration could not be killed by ivermectin, and cells treated with antioxidants (alfa-tocopherol or mannitol) were protected from ivermectin-induced death. These controls confirmed that the mechanism requires functional mitochondria and that oxidative stress is a necessary mediator.

The selective pressure on cancer cells versus normal cells through this pathway appears to relate to the elevated mitochondrial mass and higher baseline oxygen consumption rate (OCR) observed in many cancer cell types, which creates a greater dependency on uninterrupted mitochondrial function.

Mechanism 3: WNT/β-Catenin Pathway Inhibition

The WNT-TCF Pathway: A Fundamentally Important Cancer Driver

The WNT signaling pathway is one of the most intensively studied in cancer biology. In its canonical form, WNT ligands bind to cell-surface receptors, ultimately preventing the degradation of β-catenin. β-Catenin then accumulates in the cytoplasm, moves into the nucleus, and forms a complex with TCF (T-cell factor) transcription factors. This WNT-TCF complex then drives the expression of target genes that promote cell division, prevent differentiation, and support tumor stem cell maintenance — genes including CYCLIN D1, MYC, AXIN2, LGR5, and ASCL2.

In many cancers, this pathway is constitutively activated, meaning it is permanently switched on regardless of whether WNT ligands are present. In colorectal cancer, for example, approximately 90% of cases carry a loss-of-function mutation in the tumor suppressor APC, which normally helps destroy β-catenin. Without functional APC, β-catenin builds up continuously and drives relentless TCF-dependent transcription. Similar constitutive WNT-TCF activation occurs in lung cancer, glioblastoma, melanoma, and breast cancer, among others.

Despite the biological importance of this pathway, no WNT-TCF pathway inhibitors have yet entered routine clinical use. This gap makes the discovery of ivermectin's WNT-TCF blocking activity particularly significant from a drug repositioning perspective.

Ivermectin as a WNT-TCF Antagonist: The 2014 Research

A 2014 study by Ruiz i Altaba and colleagues at the University of Geneva, published in EMBO Molecular Medicine (PMC4287931), conducted a repositioning screen of over 1,040 clinically tested compounds to identify WNT-TCF response blockers. Ivermectin — specifically the precursor avermectin B1 — emerged from the screen with greater than 55% repression of TCF-luciferase reporter activity. The study then systematically characterized ivermectin's WNT-TCF blocking mechanism and efficacy.

Mechanism of inhibition: Ivermectin inhibits WNT-TCF pathway responses at low micromolar concentrations (1–5 µM). It acts by repressing specific phosphorylated forms of β-catenin at the C-terminus (P-Ser552 and P-Ser675) — forms that are required for active TCF-driven transcription. The effect appears to work through enhancement of serine/threonine phosphatase activity (specifically PP2A), which dephosphorylates these activating sites on β-catenin, reducing its transcriptional output. Crucially, this mechanism is independent of ivermectin's chloride channel effects, as it is active at concentrations 10 times lower than those needed for chloride channel disruption.

Cancer types and specific data:

• Colon cancer: Tested in multiple cell lines (DLD1, Ls174T, HT29) and primary patient-derived samples (CC14, CC36, mCC11). IC50 for proliferation inhibition (BrdU incorporation): 1–2.4 µM. Spheroid formation — a key measure of cancer stem cell activity — was reduced by up to 73% after ivermectin pre-treatment.
• Lung cancer: Tested in H358 non-small cell bronchioalveolar carcinoma. Ivermectin suppressed xenograft tumor growth by approximately 50% in mouse models given 10 mg/kg daily by intraperitoneal injection.
• Glioblastoma: Primary patient-derived glioblastoma cells showed proliferation inhibition at 1–2 µM, consistent with colon cancer lines.
• Melanoma: U251 and SKMel2 cells showed similar IC50 values (1–2 µM BrdU inhibition).

Target gene repression: qRT-PCR analysis (at 12 hours post-treatment) confirmed repression of direct WNT-TCF target genes including AXIN2 (reduced to 0.6-fold), LGR5, and ASCL2. Expression of the cell cycle regulator CYCLIN D1 was also suppressed. The tumor suppressor p21 was upregulated more than 1.5-fold. This pattern closely mimics the gene expression signature of a dominant-negative TCF construct, confirming that ivermectin is specifically blocking TCF-dependent transcription.

Rescue experiments confirming pathway specificity: The researchers conducted epistasis experiments to confirm mechanistic specificity. When a constitutively active TCF-VP16 construct was introduced, it shifted ivermectin's IC50 more than 2-fold and restored CYCLIN D1 expression and target gene levels — proving that ivermectin's effect is specifically working through TCF, not through an off-target mechanism. The okadaic acid (OA) phosphatase inhibitor reversed the reduction in phospho-β-catenin and CYCLIN D1, confirming the role of phosphatase activation.

Selective efficacy in TCF-dependent tumors: The study's xenograft data were particularly instructive: ivermectin was effective against DLD1 and HT29 colon tumors (which have constitutive WNT-TCF activation) but had no effect on CC14, a primary colon cancer line that does not depend on WNT-TCF signaling. This selectivity suggests ivermectin's WNT-TCF inhibition specifically targets cancers that are "addicted" to this pathway, while sparing tumors and normal tissues that are not.

Mechanism 4: Cancer Stem Cell Targeting

The Cancer Stem Cell Problem: Why Tumors Come Back

Cancer stem cells (CSCs) are a small subpopulation within tumors that possess properties normally associated with healthy stem cells: the ability to self-renew indefinitely, differentiate into other cell types, and generate entirely new tumors. They represent perhaps 1–5% of total tumor mass, but they are disproportionately responsible for two of oncology's most difficult clinical challenges: tumor recurrence and treatment resistance.

Standard chemotherapy drugs and many targeted therapies are highly effective at killing rapidly dividing cells. The problem is that CSCs often divide slowly and express high levels of drug efflux pumps (including P-glycoprotein, discussed in Mechanism 5). As a result, when chemotherapy destroys the bulk of a tumor, the CSC population frequently survives — and then regenerates the entire tumor. This is the biological explanation for why cancers that appear to respond to treatment often relapse months or years later, sometimes with greater aggressiveness and drug resistance than before.

CSCs maintain their stem-like state through the expression of a set of transcription factors originally identified in embryonic stem cells: NANOG (the homeobox protein), SOX2 (the sex-determining region Y-box 2 protein), and OCT4 (octamer-binding transcription factor 4). These three factors work together to preserve pluripotency, inhibit differentiation, and sustain the cell's capacity for unlimited self-renewal. In cancer, they effectively lock the CSC in a primitive, therapy-resistant state.

Ivermectin Preferentially Kills CSC-Enriched Populations

Research published in Molecular Medicine Reports by Juarez and colleagues (Juarez et al., 2017) demonstrated a striking selectivity of ivermectin for CSC-enriched cell populations in breast cancer. Using the MDA-MB-231 triple-negative breast cancer cell line — which has approximately 85% CD44+/CD24− cells, the characteristic CSC surface marker profile — the researchers made several important observations:

• At ivermectin concentrations of 4 and 8 µM, the CSC-enriched populations (both CD44+/CD24− sorted cells and spheroid cultures) showed significantly greater reduction in viability than the total cell population — a pattern called preferential killing.
• At 8 µM ivermectin, viability of the CD44+/CD24− CSC subpopulation was reduced to 0%, while the non-CSC CD44+/CD24+ population showed only approximately 25% reduction.
• The cytotoxic chemotherapy drug paclitaxel showed the opposite pattern: it was more effective against non-CSC cells, leaving the CSC population relatively intact. This is precisely why paclitaxel-based regimens can shrink tumors without eliminating their capacity to regrow.
• Ivermectin significantly reduced clonogenic capacity — the ability of cells to form new colonies — at concentrations as low as 0.2 µM.

Downregulation of Stemness Genes: NANOG, SOX2, and OCT4

The Tang et al. 2021 review (PMC7505114) further clarified the molecular mechanism underlying ivermectin's CSC-targeting activity. Treatment with ivermectin significantly reduced the expression of NANOG, OCT4, and SOX2 at both the mRNA and protein levels in MDA-MB-231 breast cancer cells, measured by RT-qPCR and Western blotting after 72 hours of treatment at 4 µM.

The mechanistic link between PAK1 degradation and CSC marker suppression was also established: ivermectin inhibits the PAK1-STAT3 axis in cancer stem cells. STAT3 (signal transducer and activator of transcription 3) is a transcription factor that directly drives the expression of NANOG, SOX2, and other stemness genes. When PAK1 is degraded by ivermectin, STAT3 activation is reduced, leading to suppression of the entire stemness gene program. Without their self-renewal gene network active, CSCs begin to differentiate or die — losing the very properties that made them so dangerous.

Additional corroboration comes from a related study which showed that ivermectin also reduced the activity of aldehyde dehydrogenase (ALDH), another well-validated CSC marker, in addition to downregulating NANOG and SOX2. ALDH activity is commonly used in laboratory research as a functional marker to identify and sort CSC populations, and its reduction by ivermectin confirms a broad effect on CSC biology rather than a narrow marker-specific effect.

Clinical Significance: Addressing the Root of Recurrence

The implications of ivermectin's CSC-targeting activity are potentially significant in a clinical context. If a treatment protocol could combine standard cytoreductive therapy (to shrink the bulk tumor) with an agent that specifically eliminates the CSC population, the resulting elimination of the tumor's regenerative reservoir could substantially reduce relapse risk. The fact that ivermectin appears to act against CSCs through mechanisms (PAK1 degradation, STAT3 inhibition, stemness gene downregulation) that are distinct from how most chemotherapy drugs work means it could theoretically complement existing treatments rather than compete with them.

Mechanism 5: Reversing Drug Resistance via P-Glycoprotein Inhibition

P-Glycoprotein: The Drug Ejection Machine

P-glycoprotein (P-gp, also known as multidrug resistance protein 1 or MDR1, encoded by the ABCB1 gene) is one of the most clinically important obstacles in cancer treatment. It is an ATP-powered efflux transporter — essentially a molecular pump embedded in the cell membrane — that actively ejects a wide range of chemotherapy drugs out of cancer cells before they can reach effective intracellular concentrations. When cancer cells overexpress P-gp, they develop what is called multidrug resistance (MDR): simultaneous resistance to structurally unrelated chemotherapy drugs, including doxorubicin, vincristine, vinblastine, paclitaxel, etoposide, and colchicine.

MDR is a major cause of treatment failure in several cancers including leukemia, breast cancer, lung cancer, and colorectal cancer. P-gp overexpression correlates with poor prognosis and reduced response to first-line chemotherapy across multiple cancer types. The pharmaceutical industry has invested heavily in developing P-gp inhibitors, but most candidates have either been too toxic or shown insufficient potency in clinical settings.

Ivermectin as a Potent P-gp Inhibitor: The 1996 Discovery

Ivermectin's P-glycoprotein inhibitory activity was actually the first anti-cancer mechanism discovered, in a 1996 study by Didier and Loor at Strasbourg University (Didier & Loor, 1996), making this chronologically the original observation that sparked interest in ivermectin as a potential anti-cancer compound. Using short-term functional assays measuring the restoration of Pgp probe retention in MDR cells, the researchers found that ivermectin was nearly as active as the gold-standard P-gp inhibitor SDZ PSC 833 (cyclosporin D derivative) in human lymphocytic leukemia MDR-CEM cells, and only a few-fold weaker in murine monocytic leukemia MDR-P388 cells.

The significance: ivermectin-treated multidrug-resistant leukemia cells became approximately 60-fold more sensitive to common chemotherapy drugs such as vinblastine and doxorubicin. The P-gp pump that had been ejecting these drugs was effectively disabled, allowing therapeutic concentrations to build up inside the cancer cell for the first time.

The Juarez et al. review (PMC5835698) confirmed and extended these findings, documenting that ivermectin's P-gp inhibitory effect is not limited to leukemia. Subsequent studies confirmed MDR reversal in:

• Colorectal cancer: Ivermectin treatment reduced P-gp expression in MDR colorectal cancer cell lines, restoring sensitivity to standard chemotherapy agents
• Lung cancer: Western blot analysis showed complete abolition of P-gp expression in lung cancer cells treated with ivermectin over four weeks
• Breast cancer: P-gp inhibition combined with ivermectin's other mechanisms creates a particularly potent effect in breast cancer models

A related in vivo study (Drinyaev et al.) demonstrated that avermectin B1 (closely related to ivermectin) reduced tumor growth by 50% in Ehrlich carcinoma mouse models at 1 mg/kg, and when combined with vincristine, greatly enhanced vincristine's antitumor effect — a direct demonstration of P-gp inhibition-mediated chemosensitization in living organisms.

Why This Mechanism Has Profound Clinical Implications

The P-gp inhibition mechanism is arguably the mechanism with the most immediate clinical potential — not as a standalone anti-cancer therapy, but as an agent to rescue the efficacy of existing chemotherapy regimens. For patients whose cancers have become resistant to first-line drugs, a combination of ivermectin with those same drugs could, in principle, restore sensitivity by disabling the efflux mechanism. This would allow the same drugs that stopped working to resume killing cancer cells.

The broader picture, as articulated in the Juarez review, is that ivermectin modulates multiple targets simultaneously: P-glycoprotein, the Akt/mTOR and WNT-TCF pathways, purinergic receptors, the PAK1 protein, certain epigenetic regulators (SIN3A and SIN3B), RNA helicase activity, chloride channel receptors, and stemness gene expression. This multi-target profile is unusual for any single compound and is a primary driver of scientific interest in ivermectin as a candidate for combination cancer therapies.

Bonus Mechanism: Immunogenic Cell Death — Converting Cold Tumors Hot

The Immunology of Tumor Microenvironments

One of the most significant advances in cancer treatment over the past decade has been the development of immune checkpoint inhibitors — drugs like anti-PD-1 antibodies (pembrolizumab, nivolumab) and anti-CTLA-4 antibodies that release the immune system's natural brakes and allow T cells to attack cancer cells. These drugs have produced remarkable and durable responses in subsets of patients, including some complete remissions in cancers previously considered untreatable.

However, checkpoint inhibitors only work well when tumors already contain T cells — what oncologists call "hot" tumors. The majority of tumors are "cold": they have developed mechanisms to exclude T cells and suppress immune responses, creating an immunosuppressive microenvironment that renders checkpoint inhibitors ineffective. Converting cold tumors to hot tumors — making them visible and accessible to immune attack — is one of the central challenges in immuno-oncology.

Immunogenic cell death (ICD) is a specific form of cell death that achieves this conversion. When cancer cells die in an immunogenic way, they release molecular alarm signals that attract and activate the immune system. Three hallmarks of ICD have been defined: release of ATP (which acts as a chemokine to attract dendritic cells), extracellular release of HMGB1 (high-mobility group box 1, a nuclear protein that signals danger to the immune system), and surface exposure of calreticulin (an "eat me" signal that instructs dendritic cells and macrophages to engulf the dying cell and present its antigens to T cells). When all three occur together, the result is a powerful local immune activation — and potentially, a systemic anti-tumor immune response.

Ivermectin Induces ICD: The 2021 Draganov Study

A landmark 2021 study by Draganov and colleagues at the Beckman Research Institute, published in npj Breast Cancer (PMC7925581), provided the most comprehensive evidence to date that ivermectin induces ICD and can synergize with checkpoint inhibitor therapy. The study used the aggressive 4T1 mouse model of triple-negative breast cancer (TNBC) — a particularly difficult-to-treat cancer type that is largely refractory to checkpoint inhibitors when they are used alone.

ICD hallmarks confirmed in vivo:

• Tumors isolated from ivermectin-treated mice showed large areas of HMGB1-depleted cells — meaning the HMGB1 protein had been released into the extracellular space, a key ICD signal. Untreated tumors showed uniform HMGB1 staining throughout.
• Calreticulin surface exposure was increased in ivermectin-treated tumors, providing the "eat me" prophagocytic signal.
• Ex vivo vaccination confirmed ICD: 4T1 cells treated with ivermectin in vitro were then injected into naïve mice, and these mice were subsequently challenged with live 4T1 tumor cells. Mice vaccinated with ivermectin-killed cells were protected against tumor outgrowth (p < 0.01) — the gold-standard test for ICD induction.

T-cell infiltration: Ivermectin treatment alone significantly increased both CD4+ (p < 0.01) and CD8+ (p < 0.0001) T-cell infiltration into 4T1 tumors on day 21. This T-cell recruitment is the defining characteristic of converting a cold tumor to a hot one.

Immunosuppressive cell depletion: As an allosteric modulator of the ATP/P2X4/P2X7 purinergic receptor axis, ivermectin selectively depletes immunosuppressive cell populations within the tumor microenvironment — including myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). This increases the ratio of effector T cells to regulatory T cells (Teff/Treg ratio), creating a more permissive environment for anti-tumor immune responses.

Synergy with Anti-PD-1 Checkpoint Blockade: Striking Mouse Model Results

The most clinically significant findings of the Draganov 2021 study concern the combination of ivermectin with anti-PD-1 antibody therapy. The study tested this combination in four different settings — primary tumor treatment, neoadjuvant therapy, adjuvant therapy, and metastatic disease — and found synergistic activity in all of them:

• Primary tumor setting: Neither ivermectin alone nor anti-PD-1 alone showed meaningful tumor control. The combination significantly limited tumor growth (p = 0.03) and achieved complete tumor regression in 6 out of 15 mice (40%), compared to 1/20 on ivermectin alone, 1/10 on anti-PD-1 alone, and 0/25 untreated. Statistical modeling confirmed true synergy (p = 0.008, FDR 3%). Mice with complete regressions resisted re-challenge with 100,000 live 4T1 cells in the contralateral mammary fat pad — demonstrating systemic immune memory against the tumor.
• Neoadjuvant setting: Ivermectin + anti-PD-1 + IL-2 combination achieved approximately 75% long-term survivors after surgical resection (p < 0.05), compared to near-zero survival in untreated or single-agent groups. Surviving animals showed anti-tumor T cell responses (ELISPOT reactivity against 4T1 cells) and resisted re-challenge.
• Adjuvant setting: Combination therapy (with or without IL-2) produced approximately 40% long-term survivors (p < 0.001) after surgical resection, with significantly reduced relapse. Statistical modeling confirmed synergy (p = 0.007, FDR 2%).
• Metastatic setting: Combination therapy achieved approximately 40% long-term survivors (p < 0.001) with significant metastasis reduction and confirmed synergy (p < 0.001, FDR < 1%).

A critically important control in this study compared ivermectin/anti-PD-1 combination with doxorubicin/anti-PD-1 — doxorubicin being a standard first-line chemotherapy also known to induce ICD. Doxorubicin did not convert the tumors to hot, did not induce significant T-cell infiltration, and showed no synergy with anti-PD-1 blockade. This comparison suggests that ivermectin's ICD-inducing profile is qualitatively different from conventional chemotherapy — potentially more immunogenic and less directly toxic to immune cells at clinically relevant concentrations.

Putting It All Together: A Multi-Pronged Attack on Cancer Biology

The five mechanisms — plus the bonus ICD pathway — do not operate in isolation. They are biologically interconnected in ways that may produce additive or synergistic effects within a single cancer cell, and across different populations of cells within a tumor:

Cancer Types in the Research Literature

The preclinical research on ivermectin's anti-cancer mechanisms spans a remarkably broad range of cancer types. To summarize the evidence by cancer category:

Important Context: Preclinical Evidence and the Road to Clinical Translation

The research reviewed in this article is compelling in its consistency and mechanistic depth — but it is important to understand what the current evidence does and does not show. Virtually all of the mechanistic research described here is preclinical, conducted in cell culture systems (in vitro) and mouse models (in vivo). These are necessary and important stages of research, but they do not automatically translate to effectiveness in human clinical trials.

Several factors make translation from preclinical to clinical settings challenging for ivermectin in oncology:

• Concentrations: Many of the in vitro studies used ivermectin at concentrations of 1–10 µM. Achieving and maintaining these concentrations in human tumor tissue with standard dosing is uncertain and requires careful pharmacokinetic study.
• Cancer heterogeneity: Human cancers are far more genetically diverse than the cell lines used in laboratory experiments. A mechanism that kills a homogeneous cell line perfectly may encounter resistance in the heterogeneous cell population of a real tumor.
• Tumor microenvironment complexity: Mouse tumors and cell lines do not fully recapitulate the complex immune and stromal environment of human tumors, particularly in the context of ICD and immune synergy findings.
• Clinical trials are underway: The NCT05318469 Phase I/II trial at Cedars-Sinai is testing ivermectin + balstilimab (anti-PD-1) in TNBC patients. Results from this and future trials will be essential for understanding whether the preclinical promise translates to human benefit.

None of this diminishes the scientific value of the mechanisms reviewed here. Understanding how a compound works at the molecular level is a prerequisite for rational clinical use — and the mechanistic portrait of ivermectin that emerges from this body of research is unusually rich and coherent for a drug that was not designed with cancer in mind.

Conclusion

Ivermectin's anti-cancer story is not a simple one, and that complexity is precisely what makes it scientifically interesting. Rather than hitting cancer through a single point of vulnerability, the compound engages cancer biology through at least five distinct mechanisms: degrading the PAK1 kinase to induce lethal autophagy; disrupting chloride homeostasis and mitochondrial function to deplete energy and generate oxidative damage; blocking the WNT-TCF transcription pathway to halt constitutively active growth signaling; targeting cancer stem cells by downregulating the NANOG/SOX2/OCT4 stemness program; and disabling the P-glycoprotein drug efflux pump to reverse multidrug resistance. On top of these direct anti-cancer mechanisms, emerging evidence shows it can trigger immunogenic cell death and synergize with immune checkpoint blockade to convert immune-excluded cold tumors into T-cell-infiltrated hot tumors.

For a compound already proven safe in hundreds of millions of people over decades of antiparasitic use, the mechanistic depth of its anti-cancer activity is remarkable. The research summarized here represents a scientifically grounded foundation for continued investigation — and ongoing clinical trials will determine how much of this preclinical promise can be realized in human patients.

For broader context on ivermectin's cancer research landscape, including clinical trial data and study limitations, read our companion article: Ivermectin and Cancer: What Does the Research Say?

Key References

1. Dou Q et al. (2016). Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer. Cancer Research, 76(15):4457–4469. PMC5173258
2. Tang M et al. (2021). Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacological Research. PMC7505114
3. Draganov D et al. (2015). Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via ivermectin induces a non-apoptotic and inflammatory form of cancer cell death. Scientific Reports. PMC4639773
4. Sharmeen S et al. (2010). The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells. Blood, 116(18):3593–3603. PMID 20644115
5. Melotti A, Ruiz i Altaba A et al. (2014). The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. EMBO Molecular Medicine. PMC4287931
6. Juarez M, Dueñas-Gonzalez A et al. (2018). The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. American Journal of Cancer Research. PMC5835698
7. Draganov D et al. (2021). Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. npj Breast Cancer. PMC7925581
8. Didier A, Loor F (1996). The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor. Anti-Cancer Drugs, 7(7):745–751. PMID 8949985